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A B S T R A C T   
Problem: Tumor recurrence is a major clinical issue that represents the principal cause of cancer-related deaths, 
with few targetable common pathways. Mechanisms by which residual tumors persist and progress under a 
continuous shift between hypoxia-reoxygenation after neoadjuvent-therapy are unknown. In this study, we 
investigated the role of lipid metabolism and tumor redox balance in tumor recurrence. 
Methods: Lipidomics, proteomics and mass spectrometry imaging approaches where applied to mouse tumor 
models of recurrence. Genetic and pharmacological inhibitions of lipid mediators in tumors were used in vivo 
and in functional assays in vitro. 
Results: We found that stearoyl-CoA desaturase-1 (SCD1) expressed by cancer cells and fatty acid binding protein- 
4 (FABP4) produced by tumor endothelial cells (TECs) and adipocytes in the tumor microenvironment (TME) are 
essential for tumor relapse in response to tyrosine kinase inhibitors (TKI) and chemotherapy. SCD1 and FABP4 
were also found upregulated in recurrent human breast cancer samples and correlated with worse prognosis of 
cancer patients with different types of tumors. Mechanistically, SCD1 leads to fatty acid (FA) desaturation and 
FABP4 derived from TEM enhances lipid droplet (LD) in cancer cells, which cooperatively protect from oxidative 
stress-induced ferroptosis. We revealed that lipid mobilization and desaturation elicit tumor intrinsic antioxidant 
and anti-ferroptotic resources for survival and regrowth in a harsh TME. Inhibition of lipid transport from TME 
by FABP4 inhibitor reduced tumor regrowth and by genetic — or by pharmacological — targeting SCD1 in vivo, 
tumor regrowth was abolished completely. 
Conclusion: This finding unveils that it is worth taking advantage of tumor lipid addiction, as a tumor vulnera-
bility to design novel treatment strategy to prevent cancer recurrence.  
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1. Introduction 
Systemic therapies have improved overall survival for many cancers, 
but cancer recurrence is the most shared problem of many primary 
treatment modalities for cancer [1]. How short and long-term tumor 
resurgences occur after treatment cessation, and how cancer cell adapt 
to the generated hypoxic and metabolic stresses is yet to be understood. 
Unlike normal tissue, cancer cells evolve under metabolic and oxidative 
stress conditions, which are favorable or unfavorable to their growth 
depending on their moderate or excessive levels respectively, and on the 
tumor intrinsic anti-oxidant and stress defenses [2–5]. Fluctuations in 
oxygen and nutrient disposal under an hypoxic tumor microenviron-
ment (TME) can restrict tumor growth, but can also alter cancer 
phenotype and conversion to more malignant tumors [6]. Small residual 
tumors left after chemotherapies or targeted therapies may persist under 
a continuous shift between hypoxia-reoxygenation in TME during 
treatments, and evolve later into relapse and aggressive tumors [7]. 
Naturally occurring or treatment-exacerbated hypoxia and reoxygena-
tion lead to persistent elevated oxidative stress in tumors that can alter 
the redox power of cancer cells [8]. Altered redox balance and redox 
signaling are implicated in genomic instability, tumor metabolism 
reprogramming [8,9], malignant progression and resistance to treat-
ment [10,11]. Redox equilibrium depends on the intricate interplay 
between free radical producing reactions and scavenging factor systems 
such as superoxide dismutases (SODs), catalase, glutathione peroxidase 
(GPX), glutathione reductase (GR), peroxiredoxin and thioredoxin 
[11–13]. Abnormal accumulation of reactive oxygen species (ROS) 
leading to peroxidation (-OOH) of polyunsaturated fatty acids (PUFAs) 
can trigger ferroptosis, an iron-dependent non-apoptotic cell death 
[14–16], which might play an important role in tumor sensitization to 
anticancer drugs. Cancer cell escape from ferroptosis has been reported 
as key element in resistance to drugs [17], which paved the way for 
investigations on ferroptosis inducers as potential new anti-cancer 
drugs. Yet, the upstream intricate balance between ROS and lipids 
that determines molecular-pathway driving relapse in ferroptosis resis-
tant cancers remains unknown. 
The emergence of metabolic adaptation in resistance to therapeutics 
has paved the way to the exploration of targeting metabolic vulnera-
bilities of cancer cells to overcome drug resistance [18–20]. We and 
others have reported that de novo fatty acid synthesis is an emerging key 
driver of cancer malignancy dependent on the hypoxic and metabolic 
stress induced by antiangiogenic treatment [19,21]. Several studies 
have documented the key contribution of lipid metabolism during 
cancer adaptation to acidosis [22] and of lipid addiction during cancer 
progression [19–23]. Here, we uncovered a specific role of lipid desa-
turation and transport in tumor adaptation to oxidative stress caused by 
hypoxia-reoxygenation exacerbated by TKI or cisplatin treatment and 
discontinuation. We show that lipid desaturation by SCD1 in cancer cells 
and lipid transport by FABP4 produced by tumor endothelial cells 
(TECs) promote cancer cell survival and resistance to ferroptosis in TME. 
Blocking FABP4 and SCD1 activities in tumors inhibited these processes 
and drastically reduced tumor recurrence. Our results offer the oppor-
tunity to use a novel vulnerability to block cancer progression and 
recurrence after treatment. 
2. Materials and methods 
2.1. Cell lines 
Human breast cancer (MDA-MB-231) and mouse Lewis Lung Carci-
noma (LLC) were purchased from American Type Culture Collection 
(ATCC) (Manassas, USA). Human Umbilical Vein Endothelial Cells 
(HUVEC) were purchased from Lonza. Cell line authentication for 
interspecies contamination, was performed by Leibniz-Institute DSMZ 
(GmbH, Braunschweig, Germany). Cell lines were tested by MycoALert 
Kit 139 (Lonza) to ensure that they were Mycoplasma-free before in 
vitro and in vivo experiments. Cancer cells were grown in Dulbecco’s 
modified Eagles’s medium (DMEM) and HUVECs were cultured in EBM- 
2 basal medium (Lonza, CC-3156) and EGM-2 SingleQuots supplements 
(Lonza, CC-4176). Culture medium was supplemented with 10% fetal 
bovine serum (FBS), L-glutamine (2 mM), penicillin (100 U/ml), and 
streptomycin (100 μg/ml) except EBM medium which was supple-
mented with 2% FBS. 
2.2. Human samples 
Human primary breast cancer samples (n = 23) and their corre-
sponding metastatic relapses (n = 22) were provided by the Biobank of 
the University Hospital of Liege (Liege University, Belgium). Human 
sample collection for research was conducted in accordance with the 
recognized ethical guideline of Declaration of Helsinki and approved by 
the institutional Ethics Committee of the University Hospital of Liege 
(Liege, Belgium; file #B707201111974). 
2.3. Mouse models 
In vivo tumor growth and regrowth (relapse) after TKIs (sunitinib or 
sorafenib) treatment cessation [19] and the effect of inhibitors of SCD1 
(SCD1 Inh) or FABP4 (FABP4 Inh) Inh were evaluated on MDA-M231 
xenografts grown in immunodeficient RAG1− /− mice (6–8 weeks old) 
(The Jackson Laboratory) or syngeneic LLC tumor grown in C57bl/6 
(6–8 weeks old) mice (Charles River). For the assays using SCD1 In-
hibitor (SCD1 Inh) or FABP4 Inhibitor (FABP4 Inh), mice bearing 
MDA-MB231 tumors (50–70 mm3) or LLC tumors (50–100 mm3) were 
administered with the vehicle, SCD1 Inh (40 mg/kg/day) or FABP4 Inh 
(40 mg/kg/day), in combination with TKI or by a sequential treatment 
at re-oxygenation phase. SCD1 Inh and FABP4 Inh were administered in 
mice for 30 days (for RAG− /− ) or 14 days (for C57bl/c) in combination 
with TKI or during TKI-withdrawal by gavage. For treatment with RSL3 
(20 mg/kg), drug was administered in mice bearing LLC tumors by i.p. 
injection every other day for 2 weeks. For cisplatin, BALB/c mice 
bearing 4T1 tumors (50–100 mm3) were administered by i.p. injection 
of vehicle (0.7% DMSO in PBS) or cisplatin (7 mg/kg/week) for 3 weeks. 
All animal procedures were performed according to the Federation of 
European Laboratory Animal Sciences Associations (FELASA) within the 
accredited institutional animal facility and the approved animal pro-
tocols #1990 and #1990 at Liège University, Belgium. 
2.4. Drug preparation and administration in mice 
TKIs, sunitinib malate/SU11248/SUTENT and sorafenib/Nexavar 
were purchased from LC Laboratories (Woburn, MA) and prepared as 
described previously in Ref. [19]. 
Briefly, sunitinib (4 mg/ml) was suspended in vehicle consisting of 
0.5% carboxymethylcellulose (CMC), 1.8% NaCl, 0.4% Tween-80, 0.9% 
benzyl alcohol and ultrapure water. Sorafenib (5 mg/ml) was suspended 
in Kremofor, ethanol 95%, H2O 1/1/6. Mice bearing tumors were 
treated with TKIs (sunitinib: 40 mg/kg/day or sorafenib: 20 mg/kg/day) 
for 30 days for MDA-MB231 xenografts and 15 days for LLC tumors 
followed by the drug washout period (re-oxygenation phase) that was 3 
and 2 weeks for the MDA-MB23 and LLC tumors, respectively. For in 
vitro experiments, SCD1 Inh (Abcam, ab142089) was dissolved in DMSO 
at 100 mM and stored at − 20. For in vivo studies, SCD1 Inh (DC 
Chemicals DC5893) [24] was dissolved in DMSO (vehicle) at 80 mg/ml 
as stock solution and diluted 10X in PBS before administration in mice. 
Mice bearing MDA-MB231 or LLC tumors were treated by gavage with 
vehicle (0.1 % DMSO in sterile PBS) or with SCD1 Inh (40 mg/kg/day) 
alone, in combination with TKI or after treatment cessation for the 
indicated periods. For the use of FABP4 Inh in vitro, FABP4 Inh (Bide-
pharmatech, BD62694) [25] was dissolved in DMSO at 25 mM stock 
solution and used at indicated doses. For in vivo studies, FABP4 Inh was 
prepared in 10% 1-methyl-2-pyrrolidone and 5% Kolliphor ® EL 
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(SIGMA, C5135) in sterile water. Mice bearing MDA-MB231 or LLC tu-
mors of 50–100 mm3 were administered with vehicle of FABP4 Inh alone 
(40 mg/kg/day), in combination with TKI (sunitinib) or after treatment 
cessation at indicated periods. Cisplatin (Calbiochem-CA 15663-27-1, 
SIGMA, 232120) was dissolved in DMSO at 2 mg/ml and diluted 140X 
in sterile PBS for use in mice. RSL3 (Selleckchem, S8155), was dissolved 
in a vehicle composed of (2% DMSO, 30% PEG300, 2% Tween 80, 
ddH2O). 
2.5. shRNA transduction 
MDA-MB-231 cells were transduced with shRNA lentiviral vectors 
containing Non-targeted shRNA (NT-ShRNA) (anti-eGFP) or shRNA 
directed against SCD1 (TRCN#00000337876 = shRNA n◦1, 
TRCN#00003378757875 = shRNA n◦2) (Sigma-Aldrich, St-Louis, USA). 
For mouse LLC cell line, cells were transduced with lentiviral vectors 
(vv-16.0033) containing Non-targeted shRNA (shNT) (anti-eGFP) 
(CCGGTACAACAGCCACAACGTCTATCTCGAGATA-
GACGTTGTGGCTGTTGTATTTTT) or shRNA directed against SCD1 
(TRCN#0000327815 = shRNA n◦3, TRCN#0000327889 = shRNA n◦4) 
(Sigma-Aldrich, St-Louis, USA). All transduction experiments and se-
lection with puromycin (0.5 μM) were performed at the GIGA-Viral 
vectors platform, Liège University, Liège, Belgium. 
2.6. Spheroid assay 
Spheroids were generated by seeding LLC cells (1 × 103) or MDA- 
MB231 cells (1 × 103) in each well of a non-adherent, round-bottomed 
96 well-plates (Greiner BioOne, Kremsmünster, Autria) in DMEM con-
taining 1% FBS and 20% high-viscosity methyl cellulose (Sigma Aldrich) 
or 10% FBS lipid depleted and 25% high-viscosity methyl cellulose 
(MDA-MB231 spheroids). After 24 h (LLC spheroids) and 48 h (MDA- 
MB231 spheroids) of culture, spheroids were collected, embedded in 
type I collagen gels at 2 mg/ml (BD Biosciences, San Jose, CA, USA) in 
12 well-plates, and maintained in DMEM 1% FBS or DMEM 1% FBS lipid 
depleted (for MDA-MB231 spheroids) at 37 ◦C for 24 h. FABP4 and SCD1 
inhibitors were diluted into 500 μl of DMEM and added over solid 
collagen containing spheroids. Cells were examined under a Zeiss Axi-
overt 25 microscope equipped with an Axiocam Zeiss camera and KS 
400 Kontron image-analysis software (Carl Zeiss Microscopy, Zaventem, 
Belgium). 
2.7. Viability assays 
LLC (1 × 104) and MDA-MB231 (3 × 104) cells were plated in 96 
well-plates in DMEM supplemented with 1% FBS or 10% of lipid 
depleted FBS (BioWest, Riverside, USA). Parental MDA-MB231 and LLC 
cells were incubated with vehicle, SCD1 Inh, erastin (Selleckchem, 
S7242) or deferoxamine (DFO) (100 μM) (D9533-1G Sigma) (2 h) or 
shNT and shSCD1 cells seeded overnight were starved for 1 h in 90 μl 
DMEM lipid free FBS and incubated with 10 μl of H2O2 (100 μM) for 30 
min. For experiments using FABP4 Inh, LLC (1 × 104) and MDA-MB231 
(3 × 104) cells were plated in 96 well-plates in DMEM supplemented 
with 1% FBS or 10% FBS, respectively. Parental MDA-MB231 and LLC 
cells were incubated with vehicle or FABP4 Inh, erastin or DFO for 2 h 
and incubated with 10 μl of H2O2 (100 μM) for 30 min. Viable cells were 
detected after incubation with 10 μl of 1.90 mg/ml MTS (Promega, 
Madison, USA). 
2.8. Cell proliferation 
Cell proliferation was assessed using CYQUANT assay according to 
the manufacture’s protocol. For cell proliferation assessment by Incu-
Cyte®, LLC (1 × 10 4) and MDA-MB231 (3 × 10 4) cells were plated in 96 
well-plates with DMEM 1% FBS. Data of proliferating profiles were 
collected and processed from IncuCyte (Sartorius, Göttingen, Germany). 
2.9. ROS dosage assay 
ROS measurement in cancer cells in vitro was performed using the 
DCFDA Cellular ROS Detection Assay Kit from Abcam (ab 113851) and 
according to the manufacture’s protocol. MDA-MB231 and LLC cells (25 
× 103) were incubated in DMEM supplemented with 10% FBS OVN. 
Cells were incubated with kit reagents and treated with FABP4 Inh for 2 
h prior ROS measurement. 
2.10. NADP/NADPH assay 
NADP/NADPH dosage was performed using a bioluminescent 
NADP/NADPH-Glo assay kit from Promega (G9081). Tumor lysates (10 
mg) were collected in specific buffer and luminescence was measured at 
340 nm. 
2.11. Western blot analysis 
Tumors and cell lysates were prepared as previously described in 
Ref. [19]. Total protein extracts (40 μg) were separated under reducing 
conditions on 5–15% polyacrylamide gels (depending on the molecular 
weight) and transferred onto polyvinylidene difluoride membranes 
(NEN, Boston, MA, USA). Membranes were saturated for 1 h with casein 
(1%, w/v) in PBS-Tween-20 (0.1%, v/v). Antigenic bands were detected 
by exposing the membranes to human primary antibodies targeting the 
following proteins: SCD1 [M38], SCD1 [ab52356, Abcam], TxNIP 
[D5F3E], Cell Signaling (Beverly, MA, USA), FABP4 [ab13979], GPX4 
[ab231174] Abcam (Cambridge, England), SOD1 [8B10], Catalase 
[PA5-23246] Thermofisher (Rockford, IL, USA), GPX1 [A0873] and 
serotransferrin [A1448] (Abclonal, Woburn, MA, USA). After washes, 
membranes were incubated with a secondary horseradish peroxydase 
(HRP)-conjugated goat anti-rabbit antibody (1:2000, DakoCytomation) 
or sheep anti-mouse antibody (1:1000, DakoCytomation). Immuno-
complexes were visualized by chemiluminescence reaction on a lumi-
nescent image analyzer (LAS-4000; Fujifilm, Wavre, Belgium). For 
loading control, membranes were stripped and re-incubated with Hsc70 
[B-6, sc-7298] antibody (Santa Cruz, CA, USA), or GAPDH [MAB37A] 
and actin [A2066] antibody (Sigma Aldrich, Saint-Louis, USA). 
2.12. Immunohistochemistry 
Primary antibodies and dilutions used are: Rabbit polyclonal anti- 
Lyve-1 (1/1000) (Bioconnect, Huissen, Netherlands); rabbit polyclonal 
anti-Fatty acid synthase (FASN) (1/100) (Cell signaling, #3180); rabbit 
polyclonal anti-perilipin A (1/500) (ab352, Abcam); rabbit polyclonal 
anti-carbonic anhydrase 9 (CA-IX) (1/1000) (ab15086, Abcam); mouse 
monoclonal anti-CD31 (1/40) (ab10559 Abcam); mouse polyclonal anti- 
SCD1 (1/100) (ab19862, Abcam); FABP4 (1/1200) (ab13979); PLIN2 
(1/400) (ab52356, Abcam), Pimonidazole (1/50), GPX4 (1/500) 
(ab231174, Abcam) and 4-hydroxynonenal (HNE) at 1/500 (ab46545). 
Slides of 6 μm thick were autoclaved for 11 min at 126 ◦C in Target 
Retrieval Solution (DAKO, S1699, Glostrup, Denmark) except for Lyve-1 
staining for which slides were incubated for 20 min at 37 ◦C in trypsin 
0,025% (DAKO, S2012). The procedures applied for endogenous 
peroxidase blockade was an incubation in 3% H2O2/H2O for 20 min. 
Tissues was saturated by incubation in PBS/bovine serum albumin 10% 
(Fraction V, Acros Organics, NJ) for 1 h, for the detection of FASN, 
perilipin A, and CA-IX. For CD31 staining, non-specific sites were 
blocked after incubation with normal goat serum 100% (NGS) for 30 
min at room temperature. For the detection of PLIN2, slides were 
incubated with animal free blocking solution (Cell Signaling, 15019L) 
for 20 min at room temperature (RT). For SCD1 and pimonidazole 
staining, non-specific sites were blocked by incubation with protein 
block serum free (DAKO, X0909) 10 min at RT. Tumor sections were 
then incubated with the primary antibodies, at room temperature, for 1 
h or OVN à 4 ◦C for SCD1 staining. After washes in phosphate buffered 
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saline (PBS), the appropriate secondary antibodies conjugated to 
peroxidase or biotin for 30 min were added: rabbit anti-rat/biotin 
(diluted 1/300, DAKO), goat anti-rabbit/biotin (diluted 1/400, 
DAKO), rabbit anti-guinea pig/HRP (diluted 1/50, DAKO), rabbit anti- 
rat/HRP (diluted 1/400, DAKO) and goat anti-rabbit ENVISION/HRP, 
goat anti mouse ENVISION/HRP. After washes in PBS, the antibody- 
antigen complex was visualized by treatment with 3,3′-dia-
minobenzidine (DAB, DAKO, Glostrup, Denmark). Samples were coun-
terstained with hematoxylin, washed in H2O, dehydrated in graded 
alcohols and mounted with EUKITT (Kindler GmbH, Ziegelhofstrasse, 
Freiburg). 
2.13. Immunofluorescent detection of HNE 
Detection of 4-hydroxynonenal (HNE) in cancer cells in vitro was 
performed on coverslips of sh-SCD1 or shNT MDA-MB231 cells incu-
bated or not with H2O2 (100 μM) for 30 min. Coverslips were washed 
with PBS, fixed with 4% PFA and permeabilized with 0.5% Triton x-100 
for 10 min at RT, washed with PBS and incubated with 5% BSA for 20 
min at RT. Cells were incubated with anti-HNE antibody (ab46545, 
Abcam) at 1/500 in 1% BSA/PBS for 1 h at RT. After washing, cells were 
incubated with donkey anti rabbit/Alexa Fluor 555 (A31572, Invi-
trogen) at 1/200 for 1 h at RT, and slides were mounted with DAPI 
Fluoromount G (0100–20, Souther Biothec) and analyzed by fluorescent 
microscopy (Olympus). 
2.14. Measurement of oxygen consumption and extracellular 
acidification rates 
Oxygen consumption rates (OCR) and extracellular acidification rate 
(ECAR) were measured using a Seahorse XFp Extracellular Flux 
Analyzer (Agilent) according to the manufacturer’s protocol. Cells were 
seeded in normal growth medium 24 h before measurement at a density 
of 25 × 103 cells per well for MDA-MB231 cells and 5 × 104 per well for 
LLC cells. Plates were pre-coated with Cell-Tak™ for LLC cells. One hour 
before the assay, cells were incubated in unbuffered serum-free DMEM 
(Basal DMEM, Agilent) pH 7.4, supplemented with 10 mM glucose, 1 
mM sodium pyruvate and 2 mM glutamine at 37 ◦C in a non-CO2 
incubator. Measurements of OCR and ECAR were taken before and 
after sequential injection of mitochondrial inhibitors. The respiratory 
chain inhibitors are ATP synthase complex inhibitor oligomycin (1 μM), 
ATP synthesis uncoupler carbonyl cyanide-p- tri-
fluoromethoxyphenylhydrazone (FCCP, 1 μM) and a mix of complex I 
inhibitor rotenone and complex III inhibitor antimycin A (0.5 μM each). 
The amount of DNA per well was determined using Hoechst incorpo-
ration after cold methanol/acetone fixation. Representative results of 
one experiment out of three independent experiments are shown. 
2.15. RNA extraction and RT-PCR analysis 
RNA extraction form MDA-MB231 and LLC tumors collected during 
treatment with TKIs and at different time points of the tumor reoxyge-
nation phase and The semi quantitative RT-PCR for mFASN, hFASN and 
primers were described in Ref. [19]. 
2.16. Label-free MS quantification 
The global proteomic analyses performed on MDA-MB231 xeno-
grafts treated with vehicle or TKI (sunitinib) and withdrawal was re-
ported in Ref. [19]. 
2.17. LC-MS based lipidomics 
Three tumor samples of MDA-MB231 xenografts of mice treated with 
vehicle, TKIs (sunitinib and sorafenib) (hypoxia phase), and 7, 14 and 21 
days after treatment cessation (re-oxygenation phase) were snap frozen 
in liquid nitrogen and then were subjected to lipid extraction. Lipid 
extraction and the subsequent lipid analysis were performed according 
to our previous report [26]. Briefly, tumor samples were homogenized 
with 225 μL of MeOH and 25 μL of 500 μg/L dilaur-
oylphosphatidylcholine (PC 12:0/12:0; Avanti Polar Lipids, AL, USA) 
dissolved in MeOH as the internal standard. After being left on ice, the 
solution was centrifuged at 16,000×g for 5 min at 4 ◦C, and the extracted 
solutions were subjected to LC-MS analysis. LC-MS analysis was carried 
out using a Nexera LC system (Shimadzu Co., Kyoto, Japan) equipped 
with two LC-30AD pumps, a DGU-20As degasser, a SIL-30AC autosam-
pler, a CTO-20AC column oven and a CBM-20A control module, coupled 
with an LCMS-8040 triple quadrupole mass spectrometer (Shimadzu 
Co.). The lipidmic analysis based upon physicochemical properties 
and/or spectral similarity with public or commercial spectral libraries 
was performed. Peak picking and integration were automatically carried 
out using the LabSolutions software (Shimadzu Corp.), and the results 
were then checked manually. The peak area of each lipid was normal-
ized to that of the internal standard. 
2.18. MALDI fourier transform-ion cyclotron resonance MSI analyses 
Tissue sections were prepared using a Research Cryostat Leica 
CM3050 S (Leica Microsystems Wetzlar, Germany) with the cryotome 
chamber chilled at − 25 ◦C and the specimen holder at − 15 ◦C. Fourteen 
μm-thick tissue sections were mounted onto ITO-coated microscopic 
slides (Bruker Daltonics, Bremen, Germany) adapted for MALDI mass 
spectrometry and dried 2 h in a desiccator. For matrix deposition, pu-
rified 1,5-diaminonaphtalene (1,5-DAN) was purchased from Sigma- 
Aldrich, Saint Louis, MO, USA. 1,5-DAN solution (5 mg/mL in ACN/ 
H2O/TFA 1:1:0,001) was deposited using a SunCollect automatic 
sprayer (SunChrom, Friedrichsdorf, Germany) at a flow rate of 5 μL/min 
[27]. The SunCollect System uses an optimized spray generator to pro-
duce extremely small matrix droplets. For data acquisition, mass spectra 
from whole tumor were acquired using a SolariX Fourier transform mass 
spectrometer (FTMS) (9.4 T) equipped with a MALDI ion source and a 
SmartbeamTM II laser (BrukerDaltonics, Bremen, Germany). Images 
were acquired at 40 μm resolution using FlexImaging 3.0 software 
(Bruker Daltonics). The MS method was calibrated using a phospholipid 
standards solution (PC(18:0/18:1)/PC(16:0/14:0)/PE(18:0/18:1)/PE 
(16:0/18:1); 1:1:1:1 v/v/v/v). MALDI lipid mass spectra were acquired 
in positive ion mode from 100 laser shots accumulated at each spot. The 
laser power was set to 18 % and the frequency to 1000 Hz. For broad-
band detection mode analyses, mass range was set to m/z 100–1500 and 
time of flight value was 7 ms. Approximately 8 h were required to 
achieve an image with a 40 μm spatial resolution. For statistical analysis 
of MALDI imaging data, the raw images were loaded separately in SCiLS 
Lab v2016 software (SCiLS, Bremen, Germany). Baseline subtraction 
was performed using the Top Hat algorithm as well as a weak denoising. 
The spectra were normalized by total ion count (TIC). The algorithm for 
peak peaking and spectra alignment was used from the skyline spec-
trum. The peak list was then reviewed in order to remove values selected 
from noise and to add some missing peaks. ±0.009 Da was set as the 
interval width value. For principal component analysis (PCA) analysis, 
spectra from whole tumor sections were compared. The interval width 
value was set at ±0.009 Da. Five principal components were set for the 
calculation and unit variance scaling was used. The analysis was per-
formed in individual spectrum mode. The score plots (spectra) were 
reported in three dimensions against the three first components. 
2.19. Bioinformatics analysis 
FABP4 and SCD mRNA expression levels in different cancers and the 
corresponding normal tissues were obtained from GEPIA, an interactive 
web server for analyzing the RNA sequencing expression data of 9736 
tumors and 8587 normal samples from the TCGA and the GTEx projects. 
Kaplan–Meier curves were generated with the Kaplan-Meier plotter 
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website (http://kmplot.com), using a database of public RNA-Seq 
datasets. Automatic cut-off scores were selected during queries; over-
all survival (OS) and relapse free survival (RFS) were selected and log- 
rank p-values were computed. 
2.20. Image processing and computerized quantification of IHC staining 
Image processing and computerized quantification of IHC staining 
densities were performed and adapted by using the previously described 
(14). Histological section images were registered in the full color red, 
green, bleu (RGB). On those images, blood (CD31), perilipin-I (adipo-
cytes), lipid droplets marker, PLIN2, and FASN, FABP4, SCD1 and GPX4 
stainings were visualized as brownish color. Blood vessel and lipid 
droplet lumens were identified as the lightest structures in the tissue (the 
value of the threshold depends on the average value of the background). 
To avoid the selection of other structures (for example, holes in the 
tissue), only lumens neighboring the detected vessels or lipid droplet 
walls were considered. It is worth noting that binary images resulting 
from the image processing described above were systematically 
compared to the corresponding originals and in the few cases that 
automatic feature detection was not accurate, threshold was adapted 
manually. Results are expressed as density of staining defined as the area 
occupied by these specific detected markers divided by the total area of 
tumor. Image processing and measurements were performed using the 
toolbox of image analysis of the MATLAB 9.4 (R2018a) software 
(Mathworks, Inc.). 
2.21. Statistical analysis 
Considering in vitro experimentation, differences between experi-
mental groups were assessed using a Mann-Whitney test using Prism 7.0 
software (GraphPad, San Diego, CA). For computerized images analysis, 
statistical analysis was performed using the statistic toolbox of Matlab 
(9.4) 9 (R2018b) software (Mathworks, Inc.). The results were expressed 
as the mean ± standard error of the mean (SEM). A non-parametric 
Mann-Whitney significance test was used to compare the median 
values measured for the groups. Results were considered significant at p 
< 0.05. In vivo, to compare differences between mice treatments we used 
a multiple comparison ANOVA two ways with Holm-Sidak parameter 
using SigmaPlot software (SYSTAT, San Jose, CA). 
3. Results 
3.1. Post therapy mouse residual tumors are enriched in hypoxia and 
oxidative stress markers and have altered lipid metabolism 
Built on our previous finding that TKI treatment and cessation 
enhanced de novo lipid synthesis and relapse [19], we investigated the 
impact of hypoxia-reoxygenation on lipid dynamics in tumors. We used 
xenografts of human triple-negative breast carcinoma MDA-MB231 cells 
and a syngeneic mouse model of lung cancer (LLC) administered with 
TKI (sunitinib 40 mg/kg/day) (Fig. 1A) and, the syngeneic model of 
mouse mammary tumor (4T1) treated with cisplatin (7 mg/kg/week). 
Tumors were collected at different time points during (Hypoxia) and 
after treatment discontinuation (Reoxygenation). Assessment of hypoxia 
induced by treatment was conducted by immunohistochemical (IHC) 
analysis of the hypoxia marker, carbonic anhydrase 9 (CAIX, also known 
as CA9), (Fig. 1B, C and D). As expected, a drastic increase in CAIX was 
revealed during treatments with TKI or cisplatin, referred to herein as 
the “Hypoxia-phase” (Fig. 1B–D). CAIX production was progressively 
reduced after treatment cessation, thus reflecting tumor reoxygenation 
in the “Reoxygenation-phase”. 
To check whether hypoxia-reoxygenation is associated with alter-
ations in the redox balance in tumor that might increase tumor 
aggressiveness, we assessed the levels of oxidative stress markers by 
proteomic analysis of tumor and stroma proteins derived from MDA- 
MB231 xenografts (Fig. 1D and E). An increase in the expression of 
cellular antioxidant defense systems of tumor was obvious with a 
striking 25-fold change in the human catalase and a 15-fold increase of 
glutathione-S-transferase-2 (GSTM2) in TKI treated tumors and discon-
tinuation versus vehicle treated tumors (control) (Fig. 1E). Moreover, an 
increase in mouse catalase (27-fold), GSTM1 (19-fold), SOD1 (10-fold) 
and superoxide dismutase Mn (SOD2) (12-fold) was detected in the 
tumor stroma of TKI treated xenografts compared to control (Fig. 1F). 
Furthermore, a decrease in NADPH pool in tumors confirmed the pres-
ence of an elevated oxidative stress in tumors under hypoxia and reox-
ygenation (Fig. S1A). All together these data indicate a general 
mobilization of intrinsic antioxidant tumor resources to survive and 
regrow in oxidative stress amplified by hypoxia/reoxygenation in the 
TME. 
To check for a specific lipid profile in tumors, we applied matrix- 
assisted laser desorption/ionization (MALDI) Fourier transform-ion 
cyclotron resonance (FTICR) mass spectrometry-imaging (MSI) anal-
ysis to tumor sections of MDA-MB231 tumors during hypoxia and at 
different time points after reoxygenation (Fig. 1G). Each data point in 
the plot of the principal component analysis (PCA) represents a mass 
spectrum corresponding to a particular lipid class. The PCA revealed a 
strong and progressive shift in the whole lipid profile of tumors from the 
hypoxia phase to the reoxygenation-phase. This shift in lipid profile 
detected during reoxygenation-phase was associated with increased 
expression of fatty acid synthase (FASN) and perilipin-1, a lipid droplet 
(LD) coating protein and marker of mature adipocytes (Fig. S1B and C). 
FASN mRNA was induced as early as 2 days after reoxygenation in LLC 
and 14 days in MDA-MB231 tumors (Fig. S1D and E). 
3.2. Unsaturated fatty acids (FAs) and anti-ferroptotic response are 
enhanced in residual tumors 
The apparent general shift in the lipid profile prompted us to seek for 
specific classes of lipids by liquid chromatography-mass spectrometry 
(LC-MS) analysis of fresh tumor samples (Fig. 2A). Semi-quantitative 
lipidomic analysis revealed an increase in free fatty acids (FFA) after 
Fig. 1. Enhanced oxidative stress and change in the lipogenic profile of residual tumors. (A) Schematic illustration of the in vivo models of hypoxia-reoxygenation. 
Mice bearing MDA-MB231 or LLC tumors were treated with tyrosine kinase inhibitor (TKI: sunitinib 40 mg/kg/day) for the indicated periods (hypoxia in blue) and 
then the treatment was stopped (Reoxygenation). Tumors were collected one day after treatment cessation (day 0) corresponding to the hypoxia-phase or at the 
indicated time points of reoxygenation-phase after treatment cessation (7, 14 and 21 days for MDA-MB231 tumors and 9 days for LLC tumors). For mice bearing 4T1 
tumors, mice were treated by i.p. injection of cisplatin (7 mg/kg/week) for 3 weeks and euthanized 3 days after the last injection (hypoxia-phase) and 14 days after 
treatment cessation and tumor regrowth (reoxygenation-phase). (B,C) Immunohistochemistry analysis of hypoxia by CAIX staining (images) and computerized 
quantification of CAIX density (graphs) on whole tumor sections of MDA-MB231 xenografts (B) or LLC tumors (C), collected at indicated time points. *P ≤ 0,05; **P 
≤ 0,01. (D) Representative images of immunohistochemistry analysis of hypoxia by CAIX staining of 4T1 tumors treated with vehicle (Control), cisplatin (Hypoxia) 
and cisplatin discontinuation (Reox). (E, F) Global proteomic analysis of oxidative stress markers in MDA-MB231 xenografts during the reoxygenation-phase as 
compared to vehicle treated tumors. Human (E) and mouse (F) proteins found in tumor stroma were distinguishable and presented separately. Catalase, SOD1, SOD2, 
glutathione-S-transferase (GSTM1 and GSTM2) and thioredoxin (TXN) were increased in cancer and stromal cells of tumors in the reoxygenation-phase. (G) Mass 
spectrometry imaging (MALDI imaging) of lipid species on slides of tumor sections revealing differences in the PCA analysis when comparing tumors in hypoxia to 
tumors after reoxygenation (Reox at day 7, 14 and 21). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of 
this article.) 
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reoxygenation. We also noticed an enrichment of tumors in mono- and 
polyunsaturated fatty acids (MUFAs and PUFAs) after reoxygenation 
with a progressive increase in lipid desaturation at day 7, 14 and 21 after 
TKI cessation. Predominantly, the acyl chains of phosphatidylethanol-
amine (PE) and Lysophosphatidylethanolamine (LPE) composing cell 
membranes were enriched in unsaturated FAs in tumors during the 
reoxygenation-phase. To exclude the possibility that changes of lipid 
profile were a consequence of the chemical composition of the used TKI 
(sunitinib), we tested sorafenib, another TKI with a different chemical 
structure and composition (Fig. S2A). Tumors treated with sorafenib and 
collected 21 days after reoxygenation displayed similar lipidomic profile 
as sunitinib treated tumors collected at the same time point (Fig. S2A 
and B). 
Simultaneously, the increase in MUFAs was associated with an 
upregulation of the Stearoyl-CoA Desatures-1 (SCD1), the key enzyme 
that inserts double bonds into acyl chains. Detection of SCD1 in tumors 
by IHC staining revealed its increase during the reoxygenation-phase in 
both MDA-MB231 (Fig. 2B) and LLC (Fig. 2C) tumors. 
Given that enrichment of PUFA in tumors could result from increased 
lipid uptake from TME, we checked for FA transporters that shuttle 
PUFA in cancer cells. Interestingly, the lipid transporter FABP4 was 
upregulated in tumors during hypoxia and reoxygenation-phases as 
shown by Western blot analysis in MDA-MB231 and LLC tumor lysates 
(Fig. 2D and E). IHC analysis and quantification of staining density 
confirmed FABP4 increase in the hypoxic tumors with a sustainable 
expression during the reoxygenation-phase (Fig. 2F and G). Conversely, 
FABP4 was not detected in MDA-MB231 or LLC cells cultured in vitro 
(Fig. S2C), but it was abundant in serum containing medium (Fig. S2D). 
FABP4 in tumors was mainly immunodetected in adipocytes (Fig. 2H) 
and tumor endothelial cells (TECs) (Fig. 2I) rather than in cancer cells. In 
sharp contrast, FABP4 was faintly detected in the stroma of untreated 
tumors (control). Double IF staining of CD31 and FABP4 confirmed an 
increase in CD31+/FABP4+ TECs during hypoxia and reoxygenation- 
phase (Fig. 2J). 
The enrichment of MUFA and PUFA in tumors after reoxygenation 
might support cancer cell membrane fluidity and migration. Neverthe-
less, PUFA are well-known substrates of iron-mediated lipid peroxida-
tion that induces ferroptotic cell death. We next searched for ferroptosis 
markers in the proteomic data of MDA-MB231 xenogarfts and found an 
overall increase in serotransferrin (TF) and aldo-keto-reductase (AKR1c) 
in cancer (Fig. S2E) and stromal cells (Fig. S2F). Ferritin heavy chain 
(FTH1), acyl CoA synthetase long chain 1 (ACSL1) and ferritin (FTL1) 
were found increased only in stromal cells (Fig. S2F). The anti- 
ferroptosis marker, glutathione peroxidase-1 (GPX1), was 2-fold 
increased in cancer cells (Fig. S2E), and increased by 17-fold in tumor 
stroma (Fig. S2F). Notably, heat shock protein beta-1 (HSPB1), the 
negative regulator of ferroptosis and oxidative stress-induced apoptosis, 
was downregulated in cancer and stromal cells. Overall, these data 
indicate a tumor anti-ferroptotic response to lipid and ROS overload 
during recurrence. 
3.3. SCD1 and FABP4 are associated with recurrence of mouse and 
human cancers 
To check whether an anti-cancer drug different from TKI can induce 
increased expression of SCD1 and FABP4 in tumors, we used cisplatin on 
syngeneic mouse 4T1 tumors in BALB/c mice as illustrated in (Fig. 1A). 
Similar to TKI, cisplatin administration reduced tumor growth, whereas 
treatment cessation was associated with a tumor flair-up and rapid 
regrowth after drug discontinuation (Fig. 3A). Analysis of FABP4 
expression pattern by IHC on tumor sections showed an increase of TECs 
FABP4 positive cells in the TME during and after treatment, while no 
staining was revealed in cancer cells (Fig. 3B). Western blot analysis 
revealed FABP4 expression in 1:5 tumors in vehicle group, 2:5 during 
drug administration and 4:5 in tumor after regrowth (Fig. 3C), sug-
gesting an enrichment of FABP4 in tumor after treatment. IHC analysis 
of SCD1 staining in tumors (Fig. 3D) and computerized quantification of 
SCD1 density in whole tumor sections (Fig. 3E) revealed an increase in 
SCD1 expression during and after treatment, which indicates a possible 
role of SCD1 in tumor recurrence after treatment discontinuation. 
Given that anticancer drugs, but not restricted to TKI compound, can 
induce hypoxia and metabolic stress, we assessed the clinical signifi-
cance of SCD1 and FABP4 expression in a cohort of human tumors, 
which includes primary tumors and metastatic tissues of patients who 
showed relapse after first-line chemo or hormone therapy (Fig. 3F–H). 
Interestingly, IHC analysis of SCD1 (Fig. 3F) and quantification of 
staining density in whole tumor sections (Fig. 3G) revealed an enrich-
ment of SCD1 in metastatic tissues, while a faint and heterogeneous 
SCD1 staining was detected in primary tumors. In line with our exper-
imental data in (Fig. 2F and 3B), FABP4 was not detected in cancer cells, 
but found restricted to blood vessels and adipocytes adjacent to meta-
static relapse tissue of human breast cancer (Fig. 3H). Likewise, analyses 
of RNAseq datasets of TCGA and GTEx confirmed the downregulation of 
FABP4 mRNA in bulk tumors when compared to normal tissues 
(Fig. S3A). In contrast, mRNA of SCD1 was found elevated in the ma-
jority of human tumors (Fig. S3B). Next, we elucidated the prognostic 
value of SCD1 and FABP4 in cancer patients by a meta-analysis of public 
RNA-seq datasets of human cancers. Interestingly, SCD1 expression was 
associated with decreased recurrence-free survival (RFS) in all analyzed 
human breast tumors (Fig. 3I) and decreased overall survival (OS) of 
patients with clear renal cell carcinoma, cervical carcinoma (Fig. 3J), 
lung and bladder cancers, and sarcoma (Fig. S3C). While FABP4 
expression was not associated with RFS in breast cancer patients 
(Fig. 3K), its expression correlated with a decrease in OS of head and 
neck squamous cell carcinoma, lung squamous cell carcinoma (Fig. 3L), 
stomach adenoma, cervical and breast cancer patients (Fig. S3D). 
We then hypothesized that tumor adaptive response to treatment is 
orchestrated by SCD1 in cancer cells and FABP4 in TME (Fig. 3M). We 
assumed that TME-derived FABP4 could orchestrate PUFA uptake for 
lipid droplet (LD) formation in cancer cells, as essential for cell survival 
under hypoxia and for supplying PUFA in tumors for regrowth. In 
hypoxia-phase, SCD1 activity in residual tumors is inhibited by the lack 
of oxygen, whereas reoxygenation boosts its desaturase activity and 
synthesis of MUFA from saturated fatty acids (SFA), which could 
Fig. 2. SCD1 and FABP4 are upregulated by hypoxia/reoxygenation in residual tumors (A) Summary of LC-MS analyses of tumors during hypoxia and after 
different time points of reoxygenation: day 7, 14 and 21. Tables present the lipid profile as ratio between the reoxygenation and the hypoxia phases (red color 
corresponds to an increase and blue color to a decrease). The vertical axis (0–8) indicates the total unsaturation number. The horizontal axis shows lipid groups and 
their variants. The length of each bar indicates the total number of carbon atoms. N.D.: not detected; FFA: free fatty acids, Acyl, Diacyl, P (plasmanyl ether) and E 
(plasmenyl ether) indicate the binding forms of fatty acids. (B, C) Immunohistochemistry analysis (images) and computerized quantification (graphs) of SCD1 
staining density in MDA-MB231 (B) and LLC tumors (C) collected at indicated time points. *P ≤ 0,05; **P ≤ 0,01. (D, E) Western blot analysis of FABP4 in MDA- 
MB231 and (D) LLC tumors (E) treated with vehicle or TKI (hypoxia phase) and after treatment cessation (reoxygenation phase: Reox). Actin-beta was used as loading 
control. (F) Immunohistochemical analysis of FABP4 in LLC tumors treated with vehicle or TKI (hypoxia phase) and after treatment cessation (reoxygenation phase). 
(G) Computerized quantification of FABP4 staining density in whole tumor sections of tumors in (F). (H) Quantification of FABP4+ adipocytes in tumors. (I) 
Quantification of FABP4+ blood vessels in tumors. *P ≤ 0,05; **P ≤ 0,01. (J) Double-immunofluorescent staining of tumor endothelial cells (TECs) with CD31 
antibody (green) and FABP4 (red) showing an increase in FABP4+CD31+ cells in tumor after reoxygenation. (For interpretation of the references to color in this 
figure legend, the reader is referred to the Web version of this article.) 
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promote recurrence. 
3.4. FABP4 in the TME sustains lipid droplet (LD) formation and 
promotes cancer cell survival under hypoxia and oxidative stress-induced 
ferroptosis 
To explore the consequence of FABP4-mediated FA transport in tu-
mors, we examined LD formation by IF detection of PLIN2, a LD marker 
protein (Fig. 4A). Quantification revealed and enrichment of LD PLIN2+
in tumors during hypoxia, but not in the reoxygenation-phase (Fig. 4B). 
A double IF staining of PLIN2 with an epithelial marker, cytokeratin 7 
(CK7) or with an mesenchymal cell marker CD11b, demonstrated that 
lipid droplets PLIN2+ were present within CK7+ cancer cells, but not in 
CD11b + mesenchymal cells (Fig. S4A). Moreover, double staining of 
PLIN2 and pimonidazole in tumors collected from mice injected with 
pimonidazole, confirmed the increase of LD in hypoxic areas (Fig. S4B). 
The production of LD by cancer cells in response to hypoxia was vali-
dated by BODIPY 493/503, which stains neutral lipids of LD (Fig. 4C). 
Similarly, formation of LD detected by IF staining of PLIN2 was 
enhanced in cancer cells incubated in vitro under hypoxia when 
compared to normoxia (Fig. 4D). Notably, pharmacological inhibition of 
FABP4 activity, available in culture medium by a FABP4 inhibitor 
(FABP4 Inh) [25] drastically reduced LD in cancer cells (Fig. 4C and D). 
A computerized quantification of IF staining of LD PLIN2+ revealed a 
6-fold reduction of PLIN2 spots in cells treated with FABP4 Inh under 
hypoxia when compared to normoxia (Fig. 4E). These data demonstrate 
a cancer cell adaptive response to hypoxia via increased lipid storage by 
FABP4 and LD formation in vitro. 
To investigate the effect of FABP4 available in culture medium on 
cancer cell migration and growth in 3D cultures, spheroids formed by 
MDA-MB231 or LLC cells were embedded in type-I collagen gels and 
incubated with FABP4 Inh. Interestingly, FABP4 Inh inhibited spheroid 
growth and expansion in vitro (Fig. 4F and G). Similarly, FABP4 Inh 
inhibited cancer cell migration in 2D cultures of cells in the presence of 
mitomycin, an inhibitor of cell proliferation (Fig. 4H). Nevertheless, 
FABP4 Inh did not affect proliferation of LLC (Fig. S4C) and MDA- 
MB231 cells (Fig. S4D) incubated in 2D culture conditions. 
Disruption of LD has been reported to increase ROS in cancer cells 
[28]. We then tested whether inhibition of lipid uptake by FABP4 Inh 
that was shown to inhibited LD formation (Fig. 4D and E) could affect 
ROS levels in cancer cells in vitro. Interestingly, FABP4 inhibition 
resulted in a dose-dependent increase in ROS production in 
MDA-MB231 and LLC cells (Fig. 4 I). Notably, incubation of cancer cells 
under hypoxia in vitro (Fig. 4J) phenocopied the hypoxic and oxidative 
stress found in vivo (Fig. 1E). Analysis of oxidative stress and ferroptosis 
markers by Western blot and quantification revealed an increase in 
TxNIP, catalase and the anti-ferroptotic protein, GPX4, in MDA-MB231 
and LLC cells incubated under hypoxia versus normoxia conditions 
(Fig. 4J). Inhibition of FABP4 enhanced the steady-state level of TxNIP 
and GPX4 in MDA-MB231 cells and TxNIP in LLC cells incubated under 
normoxia, while their expression was not potentiated more by FABP4 
Inh under hypoxia (Fig. 4J). We next assessed cancer cells response to 
ROS in vitro after 30 min treatment with H2O2 (100 μM) and reporting 
their viability rate to control condition. Viability rate of MDA-MB231 
(Fig. 4K) or LLC (Fig. 4L) cells was reduced by 40% by H2O2 that was 
restored by NAC. Incubation with the ferroptosis inducer, erastin (10 
and 20 μM), that blocks the cystine uptake, enhanced cell death in 
MDA-MB231 than LLC cells, which appears less sensitive to this agent. 
Interestingly, FABP4 Inh (5 and 10 μM) enhanced MDA-MB231 
(Fig. 4M) and LLC (Fig. 4N) cells sensitivity to H2O2 and reduced their 
viability. We then examined whether the observed reduction in cell 
viability is due to a ferroptotic cell death by using deferoxamine (DFO), a 
non-toxic iron chelator that inhibits ferroptosis (Fig. 4O and P). Inter-
estingly, DFO resorted cell viability of MDA-MB231 (Fig. 4O) and LLC 
(Fig. 4P) cells incubated with H2O2 and erastin or FABP4 Inh. Alto-
gether, this data suggest that inhibition of FABP4-dependent lipid 
transport and uptake increased cancer cell sensitivity to ROS-induced 
ferroptotic cell death. 
3.5. SCD1-dependent production of MUFA promotes cell migration and 
protects cancer cells from oxidative stress-induced ferroptosis 
We next determined the functional significance of SCD1 found 
expressed in cancer cells by its i) pharmacological inhibition with SCD1 
inhibitor (SCD1 Inh) [24] and ii) and by its knockdown by using shRNAs 
in vitro. Human (shRNA#1 and shRNA#2) and mouse (shRNA#3 and 
shRNA#4) shRNAs-SCD1 efficacies were compared to that of a control 
shRNA (NT-shRNA) (Fig. 5A). SCD1 Inh slowed spheroid growth and 
expansion in 3D culture compared with vehicle treatment (Fig. 5B and 
C). Similarly, down-regulation of SCD1 expression by shRNA reduced 
spheroid growth and migration in 3D culture compared to control 
NT-shRNA (Fig. 5D and E). Interestingly, spheroid growth and migration 
was rescued by the exogenous (C16:1) palmitoleic acid (PA) in 
SCD1-depleted cells (shRNAs) (Fig. 5F). Suggesting that SCD1 depen-
dent MUFA production in cancer cells could affect their membrane 
fluidity, migration, proliferation and metabolic capabilities. SCD1 
downregulation was associated with a lower oxygen consumption rate 
(OCR) in cells expressing shRNA-targeting SCD1 under basal conditions 
and after FCCP challenge in the seahorse assays (Fig. 5G and H). Also, 
SCD1 inhibition resulted in a drop of cell energy that was revealed by 
ATP-linked OCR and by reduced basal and maximal respiration capa-
bilities (Fig. S4E, F). While SCD1-depleted MDA-MB231 cells did not 
show any change in ECAR under an induced energy demand (baseline 
versus stressed phenotype) (Fig. S4G), a slight decrease of ECAR baseline 
levels was noticed in LLC cells under the same stress conditions 
(Fig. S4H). These data suggest a role of SCD1 in sustaining high-energy 
demand of highly proliferating cancer cells. We further assessed 
real-time 2D cell proliferation by IncuCyte® instrument and observed a 
Fig. 3. SCD1 in cancer cells and FABP4 in the TME are associated with tumor recurrence in mouse and human cancers. (A) Tumor growth curves of 4T1 tumors in 
BALB/C mice treated with vehicle or cisplatin (7 mg/kg/week) at the indicated time points (up-arrows). Treatment cessation was associated with a rapid tumor 
regrowth that reached the volume vehicle tumors after 2 weeks of cisplatin washout. (B) Immunohistochemical analysis of FABP4 in 4T1 tumors treated with vehicle 
or cisplatin and after treatment cessation. (C) Western blot analysis of FABP4 in 4T1 tumors (n = 5) treated with vehicle or cisplatin and after treatment cessation. 
GAPDH was used as loading control. (D, E) Images of immunohistochemistry analysis of SCD1 (D) and computerized quantification of SCD1 staining density in 4T1 
tumors (E) treated with vehicle, cisplatin or after treatment discontinuation. *P ≤ 0,05; **P ≤ 0,01. (F, G) Immunohistochemistry analysis of SCD1 (F) and 
computerized quantification of staining density (G) on whole tumor sections from human primary breast cancer tumors (n = 23) and their corresponding metastatic 
relapses (n = 22) after therapies (image showing metastasis in lymph node). *P ≤ 0,05. (H) Immunohistochemistry analysis of FABP4 in human primary breast cancer 
samples (n = 23and metastatic relapses (n =22) (image showing bone metastasis). Arrows indicate FABP4+ blood vessels (BV). (I) Recurrence-free survival data 
associated with SCD1 expression levels in human breast cancers. (J) Overall survival (OS) associated with SCD1 expression in the indicated cancers. (K) Recurrence- 
free survival data associated with FABP4 expression levels in human breast cancers. (L) Overall survival (OS) associated with FABP4 expression in the indicated 
cancers. (M) Working hypothesis. Left: Residual tumors have enhanced ROS levels and increased expression of FABP4 in TECs and in adipocytes, while SCD1 activity is 
inhibited by the absence of oxygen. Thus, FABP4 may contribute to lipid uptake and LD formation in cancer cells and survival of residual tumors. Right: Reox-
ygenation boosts SCD1 activity and MUFA synthesis in cancer cells, along with the sustained expression of FABP4 in TME that can improve PUFA uptake. Lipid 
mobilization/desaturation and ROS may influence the tumor redox balance, ferroptosis and recurrence. Abbreviations: SFA, saturated fatty acids; MUFA, mono un-
saturated fatty acids; PUFA, polyunsaturated fatty acids, PUFA*, free radical of PUFA. 
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reduction of cell proliferation upon SCD1 knockdown by SCD1-shRNAs 
with a more striking effect after its pharmacological inhibition by SCD1 
Inh at 5 and 10 μM (Fig. 5I-L). 
Given that SCD1 was found upregulated in cancer cells within an 
oxidative TME, we tested its role in cancer response to oxidative stress in 
vitro. Pharmacological inhibition or knockdown of endogenous SCD1 by 
shRNA sensitized MDA-MB231 (Fig. 5M,N) and LLC (Fig. 5O, P) cells to 
H2O2 and reduced cell viability. The reduced viability induced by H2O2 
(100 μM) and erastin (10 μM) or SCD1 Inh (10 μg/ml) was restored by 
DFO in MDA-MB231 (Fig. 5Q) and LLC cells (Fig. 5R), indicating a 
ferroptotic cell death. Altogether, these data demonstrate that SCD1 
confers cancer cells with pro-migratory, proliferative and protection 
from oxidative stress and ferroptosis in vitro. 
3.6. Lipid transport and desaturation promote tumor recurrence in an 
altered TME 
To explore the cancer therapeutic potential of combining TKI with 
FABP4 or SCD1 inhibition in vivo (Fig. 6), we tested the effect of 
pharmacological inhibition of FABP4, (FABP4 Inh), as single agent or in 
combination with TKI or vehicle in mice bearing LLC or MDA-MB231 
tumors (Fig. 6A and B). As reported previously [19], TKI administra-
tion in the two experimental models resulted in tumor growth inhibition 
and rapid tumor regrowth after treatment cessation (Reox). Primary 
MDA-MB231 tumors were insensitive to FABP4 Inh (Fig. 6A), whereas 
primary LLC tumors were highly sensitive to FABP4 inhibition (Fig. 6B). 
In contrast, tumor regrowth after reoxygenation (Reox) was inhibited in 
MDA-MB231 xenografts and partially affected by FABP4 Inh (Fig. 6A 
and B). The distinct sensitivity to FABP4 Inh in the two models is likely 
due to differences in the growth properties and early onset of hypoxia in 
LLC tumors that was revealed by the use of pimonidazole in vivo and 
IHC analysis of tumor sections (Fig. S5A, B). Large hypoxic areas were 
revealed in LLC tumors (Fig. S5B), 21 days after tumor injection, 
whereas 43 days were required for MDA-MB231 tumors (Fig. S5A). 
Overall, these data suggest that inhibition of FABP4 in TME reduces the 
growth of hypoxic tumors, but partially reduces the regrowth. We next 
explored the potential of targeting SCD1 by its downregulation by 
shRNA or by its pharmacological inhibition in tumors (Fig. 6C-F). 
Endogenous silencing of SCD1 by shRNA in both MDA-MB231 and LLC 
xenografts (Fig. 6C and D) resulted in a striking inhibitory effect on 
primary tumor growth and regrowth. Pharmacological inhibition of 
SCD1 did not affect MDA-MB231 primary tumors (Fig. 6E). Combination 
of SCD1 inhibitor with TKI in the hypoxia-phase and after TKI discon-
tinuation (Hypoxia + SCD1 inh/Reox) reduced tumor regrowth. In LLC 
tumors SCD1 inh reduced primary tumors and delayed tumor regrowth 
when combined with TKI (Hypoxia + SCD1 inh/Reox) and after TKI 
discontinuation in the reoxygenation phase (Hypoxia/Reox + SCD1 inh) 
(Fig. 6F). 
Interestingly, IHC analysis of GPX4 on tumor sections of LLC tumors 
(Fig. 6G) and quantification (Fig. 6H) revealed an increase in this anti- 
ferroptotic protein during tumor regrowth in the reoxygenation phase 
that was strikingly suppressed by SDC1 inh and FABP4 Inh in vivo 
(Fig. 6G). These data indicate that SCD1 and FABP4 sustained resistance 
to ferroptosis in part through downregulation of GPX4 in an oxidative 
TME. Furthermore, a link between SCD1 and FABP4 activity and 
intrinsic expression of oxidative stress and anti-ferroptotic proteins in 
human tumors was explored by the analysis of publicly available data 
(Fig. S5C). We found that SCD1 and FABP4 expression positively 
correlated with the anti-ferroptotic protein GPX4 (Fig. S5C). This anal-
ysis revealed also that SCD1 correlated with SOD1, and FABP4 corre-
lated with TXNIP in human tumors. The pro-ferroptotic effect of SCD1 
inhibition in vivo was then validated by the IHC analysis of the lipid 
peroxide end product, 4-hydroxynoneal (HNE), in tumor sections 
(Fig. 6I). IHC analysis showed an intense deposition of HNE in cancer 
cells in the reoxygenation-phase versus hypoxia or control (vehicle) with 
more staining in shSCD1 tumors when compared to shNT tumors. HNE 
staining was elevated in hypoxia-phase (TKI) when compared to control 
(vehicle), but no significant difference was detected between shSCD1 
and shNT tumors (Fig. 6I). Furthermore, Incubation of shSCD1 and shNT 
cells under normal or oxidative stress (H2O2) conditions followed by IF 
detection of HNE, showed a striking increase of HNE in SCD1-depleted 
MDA-MB231 cells under oxidative stress, whereas to signal was found 
in control shNT cells or cells incubated under normal conditions 
(Figure S5D). All together, these in vivo and in vitro data demonstrate 
that SCD1 expression endows cancer cells with a powerful protection 
form ROS-induced ferroptosis. 
To unravel a potential link between tumor regrowth and resistance to 
ferroptosis, we assessed the effect of RSL3, the GPX4 inhibitor, in hyp-
oxia/reoxygenation model of LLC tumors. RSL combination with TKI 
and its continuation in the reoxygenation-phase (Hypoxia + RSL3/Reox 
+ RSL3) partially reduced tumor regrowth, whereas it has not effect on 
tumor regrowth when administered only in the reoxygenation-phase 
(Hypoxia/Reox + RSL3) (Fig. 6J). These data indicate a potential 
intrinsic resistance of LLC tumors to the classical ferroptosis inducer, 
RLS3. Interestingly, combination of FABP4 Inh and SCD1 Inh (Fig. 6K) 
resulted in a more efficient inhibition of LLC tumor regrowth than RSL3 
(Fig. 6J). 
Overall, we demonstrate that intrinsic lipid desaturation by SCD1 in 
cancer cells and the lipid transport by stromal-derived FABP4 reinforce 
tumor detoxification systems and promote cancer progression (Fig. 6L). 
Collectively, these data provide evidence of residual tumor adaptive 
response to hypoxia and ROS-enriched environment by FABP4 and 
SCD1, which promote cancer regrowth (Fig. 6L). Lipid mobilization and 
desaturation in an altered TME support tumor resistance to ferroptosis 
Fig. 4. FABP4-induced cancer cell migration, lipid droplet (LD) formation in hypoxia and increased cancer cell resistance to ROS-induced ferroptosis. (A–B) 
Immunofluorescence detection (A) and computerized quantification (B) of the PLIN2 in LLC tumors treated with vehicle or TKI (Hypoxia-phase) and after treatment 
cessation (Reoxygenation-phase) (n = 5). (C–E) MDA-MB231 cells were incubated under hypoxia or normoxia for 24 h with or without FABP4 inhibitor (FABP4 Inh) 
(10 μM). Cells were stained for LD with bodipy 493–503 in green (C) or stained through IF for PLIN2 (D). The graph corresponds to the mean number of PLIN2 spots 
per cell normalized to DAPI (E). (F, G) Spheroids formed by MDA-MB231 (F) or LLC (G) cells were incubated with vehicle or FABP4 Inh (10 μM) for 24 h and spheroid 
size was quantified using computerized image analysis (n = 4). (H) The migration of MDA-MB231 cells was assessed in glass inserts in the presence of mitomycin. 
Cells were incubated with vehicle or FABP4 Inh (10 μM) and allowed to migrate for 48 h. Graph corresponds to the quantification of cell surface area occupied by 
migrating cells as percentage by subtracting the surface area occupied at time t0 (n = 3). (I) Measurement of ROS levels in MDA-MB231 and LLC cells treated in vitro 
with increasing concentrations of FABP4 Inh (1–15 μM). (J) Western blot analysis of oxidative stress (TXNIP and catalase) and ferroptosis (GPX4) markers in MDA- 
MB231 (left) and LLC (right) cells incubated under normoxia or hypoxia, and treated or not for 24 h with FABP4 Inh (10 μM). Graphs correspond to densitometry 
quantifications of western blots for TxNIP, catalase, and GPX4 (n = 3). (K, L) Cell viability of MDA-MB231 (K) and LLC (L) cells pretreated for 2 h with vehicle 
(control), N-acetyl cysteine (NAC) or erastin and incubated for 30 min with H2O2 (100 μM). % of viability was determined by the ratio of cell incubated with H2O2/ 
untreated cells (n = 4). (M, N) Cell viability of MDA-MB231 (M) and LLC (N) cells after pharmacological inhibition of FABP4 by FABP4 Inh (5 and 10 μM) for 2 h and 
incubation with H2O2 (100 μM) for 30 min. % of viability was determined by the ratio of cell incubated with H2O2/untreated cells (n = 4). (O, P) Cell viability of 
MDA-MB231 (O) and LLC (P) cells pretreated for 2 h with deferoxamine (DFO) (100 μM), erastin (10 μM) and FABP4 Inh (10 μM) and incubated for 30 min with 
H2O2 (100 μM). % of viability was determined by the ratio of cell incubated with H2O2/untreated cells (n = 4). Statistical analysis was performed with Matlab 
software for LD counting in (A) and ANOVA for (E–P). *P ≤ 0,05; **P ≤ 0,01; ***P ≤ 0,001. (For interpretation of the references to color in this figure legend, the 
reader is referred to the Web version of this article.) 
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for regrowth. Finally, inhibition of FABP4 and SCD1 can be proposed as 
promising potential targets for targeting tumor resistant to ferroptosis 
and for the design of effective anti-cancer therapies that prevent 
recurrence. 
4. Discussion 
The role of metabolic rewiring during in tumor occurrence and 
resistance to therapeutics are not fully understood. Here, we provide 
evidence for SCD1 activity in cancer cells and FABP4 activity in TECs 
and adipocytes as key drivers of tumor growth in an altered TME caused 
by hypoxia-reoxygenation. By combining lipidomics, proteomics, 
MALDI-imaging, data mining, in vivo assays with pharmacological in-
hibitors, in vitro cell-based assays and detoxification systems analyses, 
we revealed the key role of fatty acid transport and desaturation in 
tumor survival and regrowth under oxidative stress. More specifically, 
we found that SCD1 and FABP4 protect tumors from ROS-induced fer-
roptosis and promote regrowth. Pharmacological inhibition of SCD1 and 
FABP4 restored ferroptosis and impaired tumor recurrence. 
Metabolic vulnerabilities of cancer and endothelial cells were pro-
posed as key targets to combat cancer [29,30], although metabolic 
heterogeneity and plasticity of tumors may hamper drug efficacy and 
lead to resistance [31–33]. Besides, changes in TME can greatly influ-
ence metabolic pathway [34]and might be a challenge for drugs tar-
geting cancer metabolism. A major aspect of theses changes in TME is 
tumor hypoxia. While it is well conceived that uncontrolled proliferation 
overwhelms the existing vessels and causes tumor hypoxia [35], anti-
cancer drugs can exacerbate tumor hypoxia, which can driver drug 
resistance [36,37]. Previously, we provided evidence of fatty acid 
addiction of tumors exposed to anti-angiogenics of TKI family [19]. 
Elevated rate of FASN and lipid synthesis promoted fast tumor regrowth 
after TKI (sunitinib or sorafenib) cessation. Recently we reported a 
lipogenic phenotype and enrichment in lipid droplets (LDs) in residual 
tumors of ovarian cancer xenografts treated with Avastin [38]. Inter-
estingly, lipid metabolism appeared as key driver of drug resistance 
[39], and FASN has been proven important for cancer cell growth and 
survival [40]. More recently, FASN activity has been demonstrated as 
required in sustaining immunosuppressive activity of regulatory T cells 
in tumors [41]. Though, small-molecule FASN inhibitors (C75 and 
GSK837149A) have shown promising results in preclinical models [42], 
but these compounds failed to show efficacy as clinical tools, due to 
severe toxicities [43]. Alternatively, we found SCD1 and FABP4 are key 
lipogenic targets of tumor recurrence. Beyond TKI treatment, these two 
proteins were also upregulated in mouse tumors treated with cisplatin, 
and in relapses of human breast cancer samples derived from patients 
treated with chemotherapy or hormone therapy. 
Lipid desaturation in cancers has been reported to play a role in drug 
resistance [17], but its mechanism of action was not described. We 
demonstrate a new function of SCD1 by which increased MUFA syn-
thesis protects cancer cells from ferroptosis, lipotoxicity of SFA, pro-
motes migration, and stimulates tumor regrowth. Accordingly, SCD1 has 
been demonstrated as a key target of PI3K-AKT-mTOR pathway by 
which ferroptosis resistance is triggered in cancer cells [44]. From TME 
side, we show that FABP4, a known PUFA shuttle [45], promotes 
migration and protection of cancer cells from ROS-induced lipotoxicity 
and contributes to tumor recurrence. 
Ferroptosis inducers are potential new therapeutics that can reverse 
drug resistance [15–17]. However, many cancer cells have an intrinsic 
resistance to ferroptosis inducers [44,46]. We have noticed that LLC 
cells are less sensitive to erastin, the drug that depletes cysteine in cancer 
cells by blocking Xc− system, the antiporter of glutamate/cysteine. 
While erastin has limited pharmacokinetic activity that prevents its use 
in vivo, we used RSL3, the anti-GPX4 drug, in an attempt to exacerbate 
ferroptosis in the reoxygenation-phase. Treatment with RLS3 resulted in 
a partial inhibition of tumor regrowth after TKI cessation, indicating a 
potential resistance to RSL3 during the recurrence of LLC tumors. 
Interestingly, GPX4 expression was reduced in tumors treated by SCD1 
and FABP4 inhibitors, supporting that increased MUFA/PUFA availably 
and dynamics can lower ferroptosis induced by ROS through the 
expression of GPX4. Accordingly, Inhibition of SCD1 or FABP4 sensi-
tized cancer cells to ROS in vitro through induction of ferroptosis, a 
process that was validated by the rescue of cell viability by DFO. 
Remarkably, downregulation of SCD1 showed a strong deposition of 
HNE in tumors under hypoxia/reoxygenation in vivo and in vitro in cells 
under oxidative stress, which consolidate the role of SCD1 as key 
anti-ferroptotic protein. 
While FABP4 expression appeared downregulated in several human 
tumors, we show that pharmacological inhibition of FABP4 efficacy on 
primary tumor growth is dependent on the occurrence of hypoxia. 
Upregulation of GPX4 by hypoxia in vitro in two different cell lines 
(Fig. 4J) demonstrate a cancer cell rapid adaptation to hypoxic stress 
that was more striking in the highly proliferative and hypoxic LLC cells 
when compared to MDA-MB231, which may help counter ferroptosis in 
hypoxia. Accordingly, the highly proliferating and hypoxic LLC primary 
tumors were more sensitive to FABP4 Inh than MDA-MB231 xenografts. 
These data point to a potential crucial role of hypoxia in the regulation 
of ferroptosis in cancer, further future studies are required to elucidate 
the potential link between HIF1/2α stabilization and regulation of 
GPX4, FABP4 and ferroptosis in tumor hypoxia. Several reports have 
demonstrated anti-tumor efficacy of targeting FABP4 by siRNAs, which 
decreased the occurrence of metastases, in several organs in mice [47]. 
We noticed an enrichment of FABP4 derived from TME of residual tu-
mors after TKI or cisplatin treatment, while another group reported a 
key role of FABP3 and FABP7 derived from cancer cells in response to 
hypoxia-reoxygenation driven by Avastin treatment in glioblastoma 
[20], suggesting a potential specific role of FABPs derived from different 
Fig. 5. Cancer cell-derived SCD1 enhanced cell migration and protection from ROS-induced ferroptosis (A) Western blot analysis of SCD1 expression in LLC 
and MDA-MB231 cells incubated with shRNA against SCD1 (shSCD1) and control shRNA (shNT). (B, C) Inhibition of spheroid growth of MDA-MB231 (B) and LLC 
cells (C) by SCD1 inhibitor (SCD1 Inh). (D, E) Inhibition of spheroid growth by shRNA directed against SCD1: shSCD1 n◦1 and n◦2 for MDA-MB231 cells (D); shSCD1 
n◦3 and n◦4 for LLC cells (E) compared to their respective control cells (shNT). Graphs are the quantifications of spheroid growth diameter (mm3) (n = 3). (F) 
Spheroid formed by LLC cells expressing shSCD1 (n◦3 and n◦4) were supplemented or not with unsaturated fatty acids (C16:1), palmitoleic acid (PA), in culture 
media. Graphs are the quantifications of spheroid growth diameter (mm3) (n = 3). (G, H) Seahorse analyses of oxygen consumption rates (OCR) upon SCD1 depletion. 
Kinetic OCR response of MDA-MB231 (G) and LLC (H) cells (transduced with control shRNA (shNT) or anti-SCD1 shRNAs after incubation with oligomycin (O, 1 μM), 
FCCP (F, 1 μM), rotenone and antimycin A mix (R/A, 0.5 μM each). Seahorse assay readouts were normalized to cell number using Hoechst incorporation (arbitrary 
unit, A.U.). Data are presented as mean ± SD, (n = 3). (I, J) Cell proliferation assessment by Incucyte of MDA-MB231 cells expressing shRNAs directed against SCD1 
or control shRNA (shNT) (I), and in (J) by pharmacological inhibition of SCD1 by SCD1 Inh. (K, L) Cell proliferation assessment by IncuCyte® of LLC cells expressing 
shRNAs directed against SCD1 or control shRNA (shNT) (K), and in (L) by pharmacological inhibition of SCD1 by SCD1 Inh. (M, N) Cell viability of MDA-MB231 (M) 
and LLC (N) cells after pharmacological inhibition of SCD1 by SCD1 Inh (10 and 20 μg/ml) for 2 h and incubation with H2O2 (100 μM) for 30 min % of viability was 
determined by the ratio of cell incubated with H2O2/untreated cells (n = 4). (O, P) Cell viability of MDA-MB231 (O) and LLC (P) cells expressing shRNAs directed 
against SCD1 or control shRNA (shNT) and incubated with H2O2 (100 μM) for 30 min. % of viability was determined by the ratio of cell incubated with H2O2/ 
untreated cells (n = 4). (Q, R) Cell viability of LLC (Q) and MDA-MB231 (R) cells pretreated for 2 h with deferoxamine (DFO) (100 μM), erastin (10 μM) and SCD1 Inh 
(10 μg/ml) and incubated for 30 min with H2O2 (100 μM). % of viability was determined by the ratio of cell incubated with H2O2/untreated cells (n = 4). *P ≤ 0,05; 
**P ≤ 0,01; ***P ≤ 0,001. 
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tumor compartments in cancer recurrence. FABP4 was also found 
expressed in the TME of ovarian cancer and mostly at the 
adipocyte-tumor cell interface that promotes cancer cell metastasis [48]. 
While FABP4 expression was restricted to TECs and adipocytes in the 
TME, we demonstrated its clear contribution in sustaining LD formation 
in cancer cells under hypoxia. Interestingly, inhibition of FABP4 in vitro, 
resulted in a disruption of LD and increased ROS and ferroptotic cell 
death in cancer cells. Whereas FABP4 Inh partially delayed tumor 
regrowth, its combination with SCD1 Inh was more effective in blocking 
recurrence of the ferroptosis resistant LLC tumors. 
Altogether, we show that SCD1-dependent lipid desaturation in 
cancer cells and lipid transport in the TME by FABP4, cooperatively 
drive recurrence after treatment by conferring resistance to oxidative 
stress and ferroptosis. 
5. Conclusions 
Tumor occurrence is one of biggest challenge of cancer therapy. 
Years on ferroptotis research have demonstrated the potential of tar-
geting ferroptosis-associated cancer progression and further explored 
ferroptosis sensitization to small molecules in primary tumors. Our work 
provides the first evidence of a tumor adaptive mechanism to ROS and 
ferroptosis during tumor recurrence. We show that hypoxia- 
reoxygenation drive this adaptation and point to the role of lipid 
transport from the TME and lipid desaturation in sustaining tumor 
regrowth. More investigations on underlying mechanisms by which 
hypoxia derived factors regulate ferroptosis in resistant tumors, could 
provide more insights into the problem of recurrence in different cancer 
types. Overall our results are potentially translatable toward novel 
therapies targeting FABP4 and SCD1 in tumor resistance and relapse. 
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